BW
CRL icon

Bravera Wealth’s Charles River Laboratories CRL Stock Holding History

Bravera Wealth’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23
Closed -$3.97K – 368
2026
Q1 		$3.97K Hold
23
– – ﹤0.01% 355
2025
Q4 		$4.59K Buy
+23
New +$4.17K ﹤0.01% 367

Other funds holding CRL

BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
JIC
Johnson Investment Counsel Cincinnati, Ohio $13.7B AUM 21.52% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $1.92B AUM 25.81% 1-Year Est. Return

Bravera Wealth's CRL Position: Q2 2026 in Review

Bravera Wealth sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 23 shares — an estimated $3.97K sold.

Bravera Wealth first reported a position in CRL in Q4 2025 and held it in 2 quarters. The position peaked at $4.59K in Q4 2025. 105 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Bravera Wealth reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
  • Bravera Wealth sold 23 Charles River Laboratories shares in Q2 2026, an estimated $3.97K.
  • Bravera Wealth first reported a position in Charles River Laboratories in Q4 2025 and held it in 2 quarters.
  • Bravera Wealth's Charles River Laboratories position peaked at $4.59K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Bravera Wealth's 13F filing for Q2 2026, filed 23 Jul 2026.